In This Section

Home / Learn / Continuing Education Activities

Continuing Education Activities


ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.
Start Courses


The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma

This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC). The program will be presented in two formats: a live, on-site learning workshop and an audio-guided online course.
Learn More


Optimizing Outcomes for Urothelial Carcinoma

With the addition of immunotherapy and other novel targeted agents to the treatment armamentarium for advanced bladder cancer, the care landscape for urothelial carcinoma is evolving. Keep the entire multidisciplinary care team up-to-date with information and resources from the ACCC education program on Optimizing Outcomes for Urothelial Carcinoma in the Community Setting. Two options for participation: a live, on-site learning workshop or as an audio-guided web course.
Learn More


Collaborative Learning Workshops to Examine Best Practices for Implementing Cancer Immunotherapies in the Community

Could your cancer care team benefit from expert guidance and strategies for coping with common challenges in delivery of immunotherapy? ACCC is offering three upcoming workshop opportunities through the Best Practices for Implementing Cancer Immunotherapy in the Community education program.
Request to Host


Case Studies in IO: A Closer Look at Care Delivery

Second in an education series, this program is offered in two formats: an on-demand audiocast and as an on-site live tumor board presentation. For this project, five ACCC Cancer Program members will have an opportunity to host Case Studies in IO: A Closer Look at Care Delivery on-site at their facility.

Organized around four case studies, the discussion will focus on current clinical evidence for optimal selection of immunotherapy and use of combination therapy. Topics covered include monitoring for and managing irAEs, care coordination and communication with non-oncology specialists, and assessment of institution- or practice-specific gaps in IO integration. Shared decision-making, reimbursement, and survivorship will also be discussed.

Online Course Live Tumor Boards

Incorporating the Latest Therapeutic Advances and Shared Decision Making Into Clinical Practice

This educational series, which includes 2 audiocasts, presents practical considerations for using novel treatments for patients with Classical Hodgkin lymphoma. The first audiocast focuses on individualizing treatment, and the second explores best practices for managing treatment-related adverse events.


Advanced Genetic Testing for Metastatic Breast Cancer Patients

The Association of Community Cancer Centers (ACCC) has joined with the Oncology Nursing Society (ONS) and The France Foundation to support a series of live Grand Rounds/Tumor Boards, “PARP Inhibitors: Advancing Personalized Medicine for Metastatic Breast Cancer Patients.”

ACCC member cancer programs are invited to participate in a live Grand Rounds program where a subject matter expert will travel to participating institutions to lead a one-hour accredited session. The Grand Rounds will provide the multidisciplinary cancer team with strategies to appropriately incorporate genetic testing and poly (ADP-ribose) polymerase (PARP) inhibitor therapy for patients with metastatic breast cancer (MBC).